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Abstract 
 
Transmissible spongiform encephalopathies (TSEs) are untreatable, fatal neurologic diseases 
affecting mammals. Human disease forms include sporadic, familial, and acquired Creutzfeldt-Jakob 
disease (CJD). While sporadic CJD (sCJD) has been recognised for near on 100 years, variant CJD 
(vCJD) was first reported in 1996 and is the result of food-borne transmission of the prion of bovine 
spongiform encephalopathy (BSE, “mad cow disease”). Currently, 230 vCJD cases have been 
reported in 12 countries, the majority in the UK (178) and France (27).  
 
Animal studies demonstrated highly efficient transmission of natural scrapie and experimental BSE 
by blood transfusion and fuelled concern that sCJD was potentially transfusion-transmissible. No 
such case has been recorded and case-control evaluations and lookback studies indicate that, if 
transfusion-transmission occurs at all, it is very rare. In contrast, four cases of apparent transfusion-
transmission of vCJD infectivity have been identified in the UK.  
 
Risk minimisation strategies in response to the threat of vCJD include leucodepletion, 
geographically-based donor deferrals and deferral of transfusion recipients. A sensitive and specific, 
high-throughput screening test would provide a potential path to mitigation but despite substantial 
effort no such test has yet appearedbeen approved. 
 
The initial outbreak of vCJD appears to be over, but concern remains about subsequent waves of 
disease among those already infected.  There is considerable uncertainty about the size of the 
infected population, and there will be at least a perception of some continuing risk to blood safety.  
Accordingly, at least some precautionary measures will remain in place and continued surveillance is 
necessaryadvisable.   
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Introduction  
Transmissible spongiform encephalopathies (TSEs) are a group of unusual neurologic diseases 
affecting mammals.  They are uniformly fatal and no treatment is available.  As the name suggests, 
the agent of the disease can be transmitted; the agent is unusual inasmuch as it is a configurational 
variant of a common cellular prion protein (PrP
C
) known as a prion (PrP
TSE
), and infection seems to 
occur in the absence of pathogen specific nucleic acid[1]. Human forms of the disease include 
sporadic, familial and acquired Creutzfeldt-Jakob disease (CJD), familial Gerstmann–Sträussler–
Scheinker syndrome (GSS) and sporadic and familial fatal insomnia (FFI). More recently, variant CJD 
(vCJD) has been recognised: a result of food-borne transmission of the prion of bovine spongiform 
encephalopathy (BSE, “mad cow disease”)[2].  
Sporadic CJD (sCJD) is diagnosed at a frequency of approximately one case per million people, per 
year, globally. Based on aetiological definition, sCJD represents the majority of cases (85%) while 
familial and iatrogenic acquired cases represent only 15% and 1%, respectively.  Of all forms of CJD, 
vCJD is unique in its aetiology because it has been transmitted through the food chain and is 
transmissible by blood transfusion[3, 4]. Even before this became apparent, there was concern 
about the possible transmission of other TSEs via transfusion but, although transmission via blood 
has been demonstrated in animal models, there have been no reported cases of human transmission 
by transfusion, other than in vCJD.  Nevertheless, a number of precautionary measures to reduce 
this potential theoretical risk have been implemented.  
In this review, we discuss the nature of human CJD and allied diseases and review data on the risk of 
transfusion-transmission of these agents. We describe current and potential approaches to minimise 
the risk of such transmission and we consider possible future directions. 
Epidemiology 
CJD  
CJD other than vCJD has been recognised for almost 100 years. sCJD occurs world-wide with an 
incidence of approximately 1 to 1.5 per million of the population per year. A very small number of 
cases occur in those less than 50 years old. The annual mortality rate in the UK has been 
approximately 1.4/ million since 2008 and is comparable to the rate in other European countries and 
other areas where effective surveillance is in place. Rates for England, Wales, Scotland, and Northern 
Ireland in the years 1990-2015 varied from  0.82 to 1.35/ million/ year[5] and were not statistically 
different. Surveillance data strongly support the conclusion that case ascertainment has improved[5] 
in the UK and elsewhere[6].There does not appear to be any geographic differences in sCJD across 
the UK, or in other countries, either looking at country, or at region of residence. 
Familial CJD (fCJD), GSS or FFI are due to genetic mutations in prion protein gene (PRNP) which cause 
abnormal forms of prion protein to be formed in the body. Over 30 different mutations have been 
identified; they are inherited as autosomal-dominant disorders.   Different mutations may produce 
different symptoms, age at onset, or length of disease, even within the same family. In fCJD, 
symptoms usually arise between the ages of 30 and 60, and disease duration generally ranges from a 
few months to 5 years. Concern about the potential transmissibility of these familial cases has 
resulted in the USA in deferral policies for family members of patients. 
vCJD 
UK cases of vCJD[5] show a slight male preponderance (58%). Median age at onset is 26 years, and at 
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death 28 years. The youngest case was age 12 at onset and the oldest was 74 years and all were 
born before 1989. Median duration of illness is 14 months, compared with sCJD where it is 4 
months. All patientscases who have been genetically analysed were methionine homozygous at 
codon 129 (129MM) of the PRNP gene, with the exception of the latest (2016) case, who was a 
methionine-valine heterozygote (129MV)[7]. 
Cases of vCJD have been spread across the UK, but individuals living in the northern half (Scotland 
and northern England) have a roughly one and a half times greater chance of developing vCJD. 
Detailed investigation has not provided any convincing evidence of demographic factors which may 
have augmented local risks for vCJD.  
Non-UK case reports 
Although first described in the UK in 1996, cases of vCJD have since been described in small numbers 
from other countries (Figure 1). Some of these individuals had a period of residence in the UK, and 
were thus subjected to a UK diet; others may have been exposed to UK beef in their country of 
residence.  
Threat to the blood supply 
CJD  
As noted, there were concerns about the possibility of transfusion-transmission of CJD even prior to 
the recognition of vCJD. These concerns were driven by the historical evidence of high rate of 
transmission of scrapie among sheep, experimental transmission of disease to non-human primates, 
and by the occurrence of sCJD transmissions in humans via injections with  growth hormone and 
gonadotropin derived from human pituitary glands, through dura mater transplants and by a few 
other rare treatments[8]: transmissions are attributable to the collection of materials from donor 
individuals with unrecognized CJD.  Animal model studies (described below) showed that infectivity 
could be present, albeit at low levels, in the blood. Significant efforts were expended undertaken to 
prevent the possibility of transmission by transfusion. In the United States, the Food and Drug 
Administration has classified CJD as a “relevant transfusion-transmitted infection”, thus requiring 
specific actions, possibly including the use of a licensed test for donors, should one become 
available[9]. A particular area of concern was the possibility of contamination of medicinal products 
manufactured from pooled plasma, because many patients would be exposed if a single infectious 
donation was included in a fractionation pool. In practical terms these concerns are no longer 
relevant for sCJD[10].. 
The actual risk of transfusion-transmitted sCJD has not been quantified and, to date, there has been 
no definitive report of such transmission in humans.  Specific studies have included case-control 
evaluations of more than 600 cases, several lookback studies involving recipients of blood from 
donors who subsequently developed sCJD, and autopsy studies on haemophiliacs exposed to pooled 
plasma products[11-17](summarised in[10]). One additional case-control study did indicate that 
blood transfusion 10 or more years before occurrence of CJD was more frequent in sCJD than in 
other neurologic diseases.[18] However, the observation could have been an artefact. Lookback 
studies reflect several thousand person-years of observation among recipients of blood from 
persons who subsequently developed sCJD and found no cases of disease[19, 20]. These studies can 
be interpreted to show that there is no such transmission, or if it occurs, it offers a much lower risk 
than that from vCJD.  
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vCJD  
Soon after the publication in 1996[21] of the first identified ten cases of vCJD, there were strong 
suggestions that vCJD would behave differently from sCJD with respect to transfusion transmission. 
Importantly, this was the first occasion in which a TSE had crossed the species barrier outside the 
laboratory settings. Secondly, it was suggested that vCJD must have been acquired through the food 
chain, and that abnormal prions had thus crossed the gut wall and gained access to neural tissue, 
presumably via gut lymphatics. There was no reason to believe that prions might not also gain access 
to the blood stream, particularly as the prion was identified in lymphoid tissues. These concerns led 
to a meeting in April 1996, convened by workers at the UK National CJD Research and Surveillance 
Unit and involving all four UK Blood Services, and the setting up of the Transfusion Medicine 
Epidemiology Review (TMER) (see later) to examine whether there was any link between blood 
transfusion and vCJD. 
The first concerns about vCJD and its potential as a threat to the blood supply were followed by 
animal studies carried out in sheep, which clearly demonstrated that BSE could be transmitted by 
blood transfusion, using experimentally infected sheep as blood donors  before the onset of clinical 
disease[22]. In December 2003[3] the first link between a human blood donor who had later 
developed vCJD and a recipient who also later developed vCJD was identified. 
Animal studies  
Early sporadically entertained experiments to investigate infectivity in the blood of animals or 
humans with naturally acquired TSEs, usually by intracerebral (i.c.) injection of blood components 
into rodents or primates, produced negative or inconclusive results [23, 24]. On the other hand 
However, later systematic studies , infectivity of blood was clearly demonstrated infectivity in blood 
in small animal studies of experimental small rodents, using mouse- or hamster-adapted TSEs[25-
28]. [36-38; consider to use as well: Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, 
Drohan WN. The distribution of infectivity in blood components and plasma derivatives in 
experimental models of transmissible spongiform encephalopathy. Transfusion. 1998 Sep;38(9):810-
6]. 
.  However, sSince 2000, studies in sheep have demonstrated highly efficient transmission of natural 
scrapie and experimental BSE by blood transfusion [22, 29, 30], and recently, infectivity was 
detected in blood samples from both vCJD and sCJD patients following inoculation into highly 
sensitive transgenic mice over-expressing either bovine or human prion protein (PRNP) ( usually 
human gene is PRNP and animal is Prnp, therefore I suggest to use “prion protein gene”) gene, 
respectively[31]. Titres of infectivity in blood and the probability of transmission by transfusion 
appear to correlate with the extent of replication of TSE agents in lymphoid tissues – transmission 
having been readily demonstrated in species/diseases with widespread lymphoid involvement (e.g. 
scrapie/BSE in sheep, chronic wasting disease in deer [32]), but not in those where lymphoid 
replication is limited (e.g. BSE in cattle [33-35]). In humans, the majority of Almost all vCJD patients 
examined to date show accumulation of PrP
TSE
, a pathognomic marker of infectivity, to varying 
degrees in lymphoid tissues including spleen, tonsil, appendix and lymph nodes [36, 37], while 
although PrP
TSE
 is rarelymay also be detected in the lymphoid tissues of sCJD cases [38, 39].  
Formatted:  Font:  (Default)  Calibri,  11  pt,  English  (Australia)
Formatted:  Title2,  Line  spacing:   Multiple  1.15  li
Formatted:  Font:  (Default)  Calibri,  11  pt,  English  (Australia)
Formatted:  Font:  (Default)  Calibri,  11  pt,  English  (Australia)
Formatted:  Default  Paragraph  Font,  Font:  (Default)  Calibri,  11  pt,  English  (Australia)
Formatted:  Font:  (Default)  Calibri,  11  pt,  English  (Australia)
Page 5 of 21 Vox Sanguinis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
6 
 
Systematic studies in rodents infected with scrapie and human TSE isolates  revealed that blood 
contains more than one thousand-fold lower levels of infectivity (10-100 infectious doses (ID)/ml) 
than brain (10
7
-10
9
 lethal doses (LD50)/g), and that titres increase as the infection progresses, 
reaching the highest values during the clinical phase of the disease [25, 27, 40, 41]. Using sheep 
infected with BSE or scrapie as an experimental model has the advantage that blood and its 
components can be collected and transfused in similar volumes to those used in human medicine. 
Thus, sheep experiments demonstrated that TSE infection can be transmitted by transfusion of 
180ml – 450ml whole blood from pre-clinical donors during the first third of their incubation period. 
Transmission rates progressively increased with the time post-infection, reaching 100% for donor 
sheep in the late preclinical and clinical stages of disease [29, 42].  
Cumulative evidence from different animal models supports the conclusion that the highest levels of 
TSE infectivity in blood are associated with leucocytes[43],[27],[44]. In sheep transfused with blood 
components from BSE-infected donor sheep, the highest transmission rates were found in those 
inoculated with buffy coat fractions [45],[30]. In the sheep scrapie model, the minimum number of 
white blood cells capable of transmitting scrapie following intravenous administration was 10
5
[46].
 
The distribution of infectivity among specific subsets of WBC (e.g. lymphocytes, monocytes, 
granulocytes) has not been clearly established, but all these cell types may be capable of 
transmitting infection to varying extents [42, 46-49].  
In sheep, prion infectivity associated with other cellular blood components (platelets, red blood 
cells) can be at least partly explained by the presence of residual leucocytes in those fractions, as 
leucodepletion appears to substantially reduce infectivity and transmission of infection [45, 50]. 
However, infectivity has been demonstrated in purified platelets from scrapie-infected sheep[25] 
and in experimentally infected deer with chronic wasting disease (CWD) by i.c. injection in highly 
sensitive transgenic mouse models expressing sheep and cervid PrP
C
, respectively [25],[47]. Thus 
platelets may play a role in blood-borne transmission of scrapie or CWD, but the relevance of these 
findings to humans is not clear.  
Plasma contains infectivity sufficient to transmit TSE infection by transfusion in sheep, but with 
much lower efficiency than whole blood or leucocytes [30, 45, 50]. This is partly due to the presence 
of leucocytes, since transmission rates were much lower following intravenous administration of 
leucodepleted or cell-free plasma [45, 50]. 
vCJD epidemic 
Primary epidemic curve and modelling to predict size in UK   
In March 1996, the probable link between vCJD and BSE in cattle was first suggested and soon 
confirmed experimentally (LC: preferred statement because in March there was no experimental 
data available yet and ref 50 is from 1997) established [21, 51, 52]. In the following 21 
years,Currently, a worldwide total of 230 vCJD cases have been reported in 12 countries (Figure 1). 
The peak number of UK cases (28) occurred in 2000, with a declining trend since then suggesting the 
primary epidemic is essentially over. The last case in the UK was diagnosed post-mortem in 2016. 
None of the 178 UK cases remain alive; the last case was diagnosed post-mortem in 2016. In France, 
the peak occurred slightly later, in 2005[53], which likely reflects the peak volume of UK origin beef 
imports during 1985-1995[54]. None of the French cases remain alive.   
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Initial modelling of the epidemic, based on 23 reported cases in the UK by January 1998, predicted  
from 29 to about 10 million cases[55]. The large upper bound reflected a number of key unknowns, 
principally the incubation period and number of people exposed per single infected bovine, which 
was speculated to be as high as 500,000[56]. In 2000, revised predictions estimated between 63 and 
136,000 cases within the genetically susceptible population (i.e. 129 methionine homozygotes (MM) 
of the PRNP gene)[57]. At the time, only preliminary data from the first tonsil /appendix study 
(Appendix-I[58] -see below) was available, with zero infections detected in 3,170 tissues examined. 
Incorporating this as a UK vCJD ‘prevalence’ rate within their modelling, and by assuming testing 
could detect infection in the last 75% of the incubation period (with 100% sensitivity and specificity), 
Ghani and colleagues[57] noted that the upper bound on total epidemic size in the susceptible 
genotype population would be reduced to from 136,000 to 80,000. 
Current modelling on UK epidemic size 
Early modelling to estimate the size of the UK epidemic was restricted to primary transmission cases 
via consumption of BSE contaminated beef and failed to consider either cases among non-129MM 
PRNP genotypes, or secondary transmission. Subsequent to the confirmation that transfusion- 
transmission was a probable route of infection[3] and the identification of a possible case involving 
an 129MV 129 methionine/valine (MV) genotype[59], new modelling was undertaken which 
expanded predictions of future cases to include 129MV and valine homozygous 129VV PRNP 
genotypes, as well as transmission via red cell transfusions[60]. Recognising that there remained 
significant uncertainty on the epidemic ‘tail’, in 2010 Garske and Ghani[60] predicted a peak annual 
incidence of around 11 cases, but with the 95% credibility interval between one and 65 cases. 
Notably, UK surveillance data subsequent to the modelling (from 2010 to 2016) record zero or one 
clinical case of vCJD per annum (Figure 1). 
Blood Safety Response 
In the late 1990s, before the link between blood transfusion and vCJD had been established, a 
number of blood safety measures were introduced in the UK[59], based on the worst-case scenario 
that vCJD could be transmitted by blood transfusion. The precautionary principle was applied, 
heavily influenced by the Phillips report[60] into the BSE epidemic.  
The first UK blood safety response, started in 1998 and implemented fully by October 1999, was to 
introduce universal leucodepletion of blood components. A definite scientific basis for this initiative 
was lacking, although preliminary results  suggested that B lymphocytes had some role in 
disseminating the infectious prion[61].  
Importation of non-UK plasma for fractionation was implemented over the same time period in the 
late 1990s. The Department of Health, advised by the Committee on Safety of Medicines, announced 
in 1998 that the fractionation of UK plasma would cease, and plasma supplies would be obtained 
from areas with a low prevalence of BSE. This decision pre-dated any decision by the regulators and 
was in part precipitated by the complexity of the requirement to withdraw batches of product 
containing plasma from individuals who were subsequently diagnosed with probable or definite 
vCJD.  
Further risk reduction measures followed. It was assumed that children born after adoption of food 
safety measures in early 1996 had not been exposed to BSE in the diet and should therefore also be 
protected, as far as possible, from non-dietary risks of infection, including blood transfusion. Safe 
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and sufficient supplies of non-UK red cells and platelets were not available, but fresh frozen plasma 
(FFP) could be sourced from outside the UK. In 2003, imported FFP was introduced for the “post-
1996” cohort and subject to methylene blue treatment to ensure that the reduction of vCJD risk was 
not replaced by an increase in the risk of transmission of blood-borne viruses. In 2004, the decision 
was taken to exclude from blood donation anyone who had been transfused since 1980. The 
following year, donors whose blood had been transfused to individuals who subsequently developed 
vCJD were also excluded.  
Geographically-based deferral for residence in affected areas 
In the absence of a blood screening test, regulatory authorities[61] and blood services in countries 
unaffected by primary cases[62, 63] sought to minimise the potential risk from vCJD. Geographically-
based deferral was based on ‘risk areas’ and ‘risk periods’ as well as defining the duration of 
‘exposure’ resulting in a ‘significant’ risk of vCJD infection. Risk areas were defined based on the 
presence of BSE and notified cases of vCJD. Most unaffected countries deferred donors with six 
months or more cumulative residence in the UK between 1980 and 1996. While the selection of six 
months exposure period was supported by modelling[61], for some blood services this period 
represented a compromise based on the associated level of donor deferral (loss), as this directly 
impacts blood product sufficiency.  
Initially, vCJD cases were restricted to the UK and deferral questions were therefore based on 
residence in the UK and territories. The risk years were based on the timing of the peak BSE 
epidemic in the UK and the assumed full implementation, by 1996, of measures to preclude the BSE 
agent from the human food chain. As cases were reported in France, some countries (e.g. USA, 
Canada) added residence in France  and other affected countries to their vCJD deferral policy. Such 
policies continue to be adjusted[64]. 
Deferral for history of blood transfusion  
The fact that vCJD may be transmitted by blood transfusion implies that transfusion recipients 
themselves might offer secondary risk of transfusion-transmission if they had received blood from 
an exposed donor with unrecognised infection.  As a result, a number of countries (e.g USA[10] and 
France) followed the UK policy of indefinite deferral for presenting donors with a history of 
transfusion, judged constituting at risk of exposure to vCJD.    
Tissue studies (tonsil/ appendix) 
The first UK tissue study looked at removed appendices for evidence of deposition of abnormal prion 
protein[65]. One out of 8318 appendices examined had positive findings, giving an estimated 
prevalence of 120 per million of the population. A further study was carried out between 2007 and 
2011, analysing tonsils by two independent EIAsimmunoassays, immunohistochemistry & western 
blot[66]. In total, approximately 150,000 tonsils were tested, and none was unequivocally positive. 
The appendix study was repeated (Appendix II) in a retrospective study on appendix samples 
collected between 2000 and 2012[67]. The samples were screened by immunohistochemistry, and 
16 of 32,441 were positive (age range born between 1941 and 1985), giving an estimated prevalence 
of 493 per million (95% CI: 282-801/million). 
Various caveats were expressed, perhaps most importantly that only appendix samples were 
confirmed reactive. It was hypothesised that the tonsil is only affected late in the disease process, 
and might therefore not be the tissue of choice for examination. Although vCJD occurs more 
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commonly in the younger age groups, reactive appendix samples were found across all age groups. It 
was proposed that many normal healthy persons could have peripheral PrP
TSE
 accumulation in the 
appendix, and it was therefore important to carry out a similar study in a BSE/vCJD free population. 
The Appendix III study looked at samples outside of the presumed BSE exposure period: those 
removed before 1980, and from young people born after 1996. 
The results of the Appendix III study have not yet been reported in detail, but a preliminary 
report[68] revealed that positive samples were found in both groups examined, but not in any 
appendix removed before 1976 or in any individual born after 2000. It could be that there is a low 
background prevalence of abnormal prion protein in appendices, unrelated to the intensity of 
exposure to BSE, or that it is related to BSE exposure and that human exposure began in the late 
1970s and continued until the mid-1990s, although at a lower rate than in the central years in the 
mid-1980s. 
 
Second wave probability  
Although the peak of vCJD cases occurred in the UK in 2000, there remains uncertainty about the 
possibility or probability of a second wave of infection.  There are two possible sources of a second 
wave. First, the development of clinical disease in those infected through diet in the past, perhaps 
due to an extended incubation period in individuals of a non-129MM PRNP genotype. The first case 
of vCJD in such an individual was reported from the UK in 2016, and was in a 129MV PRNP 
heterozygote[7, 69]. Does this represent the start of a second wave, or a random event? 
Epidemiological studies of kuru, a disease in aboriginal tribes of Papua New Guinea practicing 
cannibalistic rituals, and acquired CJD have indicated that persons with any 129MM, 129VV, 129 MV 
PRNP genotype have been infected [70, 71], although the incubation periods were more prolonged 
in 129MV individuals[72, 73].  
A second wave could also occur due to person-to-person transmission, for example though blood 
transfusion or surgical instruments. The four cases of transfusion transmission occurred in 1999 or 
earlier. If there are significant numbers of infected (and potentially infectious) carriers of vCJD in the 
UK population, as suggested by the appendix studies, it is difficult to explain why further cases of 
transfusion-associated vCJD have not appeared. There is a detailed assessment of every new case of 
vCJD, and the possibility of blood donation and/or blood receipt is examined every time a new case 
is diagnosed, so it is unlikely that there has been under-recognition of such cases. Furthermore, 
there has been no case of vCJD in a recipient exposed to multiple transfusions of blood components. 
It is estimated that there are several thousand such recipients, for example those regularly 
transfused in management of haemoglobinopathies and aplastic anaemia, and many more who are 
intensively transfused. 
It thus appears, at present, that a second wave cannot be discounted, but is most likely to be due to 
past infection through diet becoming manifest after a prolonged incubation period in non-129MM 
PRNP genotype individuals, rather than person-to-person transmission. Only time and surveillance 
will answer this question. 
Transfusion transmission 
Risk assessments 
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The US FDA has developed models to estimate the residual risk of vCJD transmission from 
transfusion in the USA.  The primary approach was to estimate the residual risk, based upon the 
assumption that some donors would have been exposed to BSE as a result of travel or residence in 
areas of significant BSE prevalence.  The risk estimate was based upon data developed in the UK, 
based on the frequency of clinical vCJD (the low estimate) or a study of appendices (the high 
estimate). The overall risk estimates for the US were one transmission in 134 million(low) to 1 in 
148,000(high) transfusions.  Overall, the low value was thought to be most likely[74]. A subsequent 
model looked at the relative risk attributable to donors with exposure in different countries, 
concluding that deferral focused on the UK and most European countries, along with leucodepletion, 
was only marginally more effective than deferrals based upon the UK, France and Ireland  (90.4% vs 
89.9%), with 35% fewer deferrals[75].  
Lookback studies 
CJD  
The American Red Cross (ARC) has been working with the US Centers for Disease Control for more 
than 20 years, in order to monitor the extent to which donors who are presumed to be incubating  
CJD may transmit the disease to recipients of their blood.  When a confirmed case of CJD is identified 
and the patient is known to have donated blood, the relevant blood collection site is asked to 
identify those hospitals that received components from the affected donor.  The recipients of those 
products are identified and their current vital status is determined and/or their identifying 
information is sought and vital status is determined by searches in the National Death Index on an 
ongoing basis.  Direct and contributing causes of death are obtained for all decedents.  As of the 
most recent report, 65 donors were identified: they had contributed a total of 1,816 components to 
the blood supply, 826 of which could be traced to recipients of whom 799 could be fully tracked. Of 
these recipients, 654 were deceased and 154 were still alive.  The total follow-up was over 3900 
person-years and no cases of CJD were identified. It is of interest to note that  414  recipients were 
transfused with blood collected just prior to the donor’s diagnosis and that 264 recipients survived 
more than 5 years post-transfusion, 44 of whom survived for more than 20 years[20]. 
vCJD  
As noted, the TMER[19] was set up to establish whether there is any link between blood transfusion 
and CJD. All types of CJD are included, but most interest has been in the vCJD arm.  
All individuals old enough to have been blood donors who have a diagnosis of probable or definite 
vCJD are notified to the UK blood services, and a search is made of donor databases to establish 
whether the case was a blood donor. If there is a record of the individual, a lookback is carried out to 
establish the fate of all blood donations and associated issued blood components. Receiving 
hospitals are notified of components issued to them, and they establish the ultimate fate of the 
components from their laboratory records. If the blood was transfused, the recipient is identified to 
the blood service and the details shared with the National CJD Research and Surveillance unit 
(NCJDRSU). Health service records are then flagged so that a copy of the death certificate will be 
forwarded to the NCJDRSU when the individual dies, and cause of death and associated illnesses can 
be determined. At the start of the study, because there was no known link between vCJD and blood 
transfusion, the identified recipients were not notified. When the first link was made in December 
2003[3] the surviving identified recipients were informed of the situation and told they were at risk 
of vCJD. In total, 67 donors developed vCJD subsequent to their donations and 68 recipients have 
been identified.   
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Three of the 68 recipients developed vCJD and died some years after transfusion from blood from 
donors who developed vCJD after blood donation. Two of the cases were linked to a common donor. 
Recipient disease was diagnosed 6.5 to 8.3 years after transfusion, which occurred in 1996 or 1997.  
The implicated donors developed vCJD 18 to 40 months after the transmitting donation.  All of these 
clinical cases were 129MM homozygous[19, 76].  
One further recipient (129 MV heterozygous) who received transfusion from a third  donor died five 
years later without any clinical signs of vCJD, but abnormal prion protein was found at post-mortem 
in the spleen and one lymph node but not in the brain.[77].  
Other deceased recipients have either had no post-mortem, or negative findings. Fourteen of 68 
identified recipients remain alive and symptom-free, and all have now passed the tenth anniversary 
since the transfusion in question. 
The TMER has performed exhaustive investigation of the donor and recipient cohorts and have 
found no further evidence of transfusion-transmitted vCJD.  Similar examinations of sporadic and 
familial CJD have failed to demonstrate any evidence of transmission[19]. 
In the reverse part of the study, people with vCJD with a history of blood transfusion are notified to 
the blood services together with the identity of the treating hospital. The blood service establishes 
the transfusion history and traces the relevant blood donors; their NHS records are also flagged. In 
this process, ten people who developed vCJD have had a history of blood transfusion confirmed, but 
only three of them are linked to donors who are known cases of vCJD. These three recipients had 
already been identified through the “forward arm” of the study, as described in the preceding 
paragraphs. So, in this reverse process, no additional cases of transfusion-transmission have been 
uncovered, which were not already known. The identified blood donors relating to the other cases 
are considered to be possible sources of the vCJD in the recipient, and are therefore at risk of vCJD. 
They  have been notified accordingly and withdrawn from the donor panel, as described in an earlier 
section, but none is known to have developed vCJD, after many almost 2400 person-years of follow-
up[78].  
After the link between blood transfusion and vCJD was established, the part of the TMER concerned 
with vCJD was reassigned from a research study to routine CJD surveillance. The research study 
continues to operate for sporadic and familial CJD cases, with negative findings to date. 
Blood safety response and eEfficacy of risk mitigation strategies Blood Safety Response 
In the late 1990s, before the link between blood transfusion and vCJD had been established, a 
number of blood safety measures were introduced in the UK[64], based on the worst-case scenario 
that, vCJD could be transmitted by blood transfusion. The precautionary principle was applied, 
heavily influenced by the Phillips report[79] into the BSE epidemic.  
The first UK blood safety response, started in 1998 and implemented fully by October 1999, was to 
introduce universal leucodepletion of blood components. A definite scientific basis for this initiative 
was lacking, although preliminary results  suggested that B lymphocytes had some role in 
disseminating the infectious prion[80].  
Importation of non-UK plasma  for fractionation was implemented over the same time period in the 
late 1990s. The Department of Health, advised by the Committee on Safety of Medicines, announced 
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in 1998 that the fractionation of UK plasma would cease, and plasma supplies would be obtained 
from areas with a low prevalence of BSE. This decision pre-dated any decision by the regulators and 
was in part precipitated by the complexity of the requirement to withdraw batches of product 
containing plasma from individuals who were subsequently diagnosed with probable or definite 
vCJD.  
Further risk reduction measures followed. It was assumed that children born after adoption of food 
safety measures in early 1996 had not been exposed to BSE in the diet and should therefore also be 
protected, as far as possible, from non-dietary risks of infection, including blood transfusion. Safe 
and sufficient supplies of non-UK red cells and platelets were not available, but fresh frozen plasma 
(FFP) could be sourced from outside the UK. In 2003, imported FFP was introduced for the “post-
1996” cohort and subject to methylene blue treatment to ensure that the reduction of vCJD risk was 
not replaced by an increase in the risk of transmission of blood-borne viruses. In 2004, the decision 
was taken to exclude from blood donation anyone who had been transfused since 1980. The 
following year, donors whose blood had been transfused to individuals who subsequently developed 
vCJD were also excluded. 
  
  
It is difficult to assess the efficacy of risk-mitigation strategies for CJD or indeed, for vCJD.  The 
absence of any definitive evidence of transmission of sporadic CJD by transfusion is really not 
informative. Suffice to say that clearly there has been exposure of recipients to blood from donors 
who have been incubating the disease; a situation not amenable to any rational intervention.  
Routine deferral of those considered to be at risk has a minimal impact on blood availability, 
although the policies may be challenging confusing for those potential donors who are 
impacteddeferred.  
A number of measures have been implemented to attempt to manage the risk of transmission of 
vCJD by transfusion.  Again, however, it is not possible to assess the efficacy of these methods, 
although with definitive evidence of transmission, it can be argued that the absence of continuing 
transfusion-associated cases may be meaningful, albeit in the face of a decline in the number of 
cases of vCJD in the general population. In the UK, an early measure to combat such transmission 
was the implementation of universal leucodepletion. The importance of this measure is evident 
when one considersIn this context, it is of interest to note that all four transmissions reported from 
the UK were traced to non-leucodepleted red cells. Subsequently, in the UK, the use of locally 
derived plasma was eliminated from transfusion for young people born after 1996, and further 
manufacture into fractionated plasma products.  Outside the UK, the broad focus has been on 
deferral from donation of potential donors with a history of travel to, and/or residence in the UK and 
parts of Europe. Outside the UK, there have been no cases of transfusion-transmitted vCJD reported, 
and vCJD reported cases have been attributed to probable dietary exposure outside the country, or 
to exposure to UK-derived beef in the country of residence. Thus, the outcome of the apparent 
success of the deferral program is not possible to evaluateabsence of transfusion-transmission of 
vCJD outside the UK cannot necessarily be attributed to the deferral policies.  It appears likely that 
deferral policies will be modified as the risk of infection from the food chain is eliminated from 
countries affected by travel deferrals. 
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Filters intended to remove TSE prions from blood or plasma have been developed, and were shown, 
inbut laboratory studies, to achieve a modest, but not complete, reduction of infectivityassess their 
usefulness were inconclusive[81]. Such filters were evaluated for potential use in the UK and the 
Republic of Ireland [82], but were not recommended for adoption. Currently, available methods for 
pathogen reduction of blood components are not effective against TSER infectivity.  
vCJD donor screening test  
Developing an appropriately sensitive and specific donor screening test has been very challenging 
and to date elusive, despite major efforts. Detection of the PrP
TSE
 by classical serological methods is 
prohibited by the absence of any immune response by the host. As well, PrP
TSE
 levels in blood are 
extremely low (in the femtomolar range) and indistinguishable by general characteristics from PrP
C
, 
which is present in very large excess.  
While the value of aA vCJD donor screening test is anticipated to be beneficial, but undeniable, the 
performance requirements for such a test must be very stringent given the serious negative 
consequences of incorrect results in the context of notification for an incurable disease with a long 
incubation period. The importance of defining appropriate performance standards for candidate 
donor screening tests led to the establishment of a European Union (EU) regulatory standard (EU 
Commission Directive 2011/100/EU) for licensing for human use which requires that tests achieve at 
least 90% sensitivity and 99.5% specificity[83]. 
Presently there are two promising candidate test methods, Direct Detection Assay (DDA) developed 
by the UK MRC Prion Unit and protein misfolding cyclic amplification (PMCA), which have 
demonstrated the capacity to accurately identify vCJD prion infection in whole blood or urine[84-
90]. Bougard and colleagues recently reported their PMCA assay was able to detect 18 patients with 
clinical vCJD among 256 plasma samples from the two most affected countries, with 100% sensitivity 
(95%CI: 81.5 to 100%) and 100% diagnostic specificity (95%CI: 96.5 to 100%)[88]. Critically, their 
assay was able to detect PrP
TSE
 in two samples collected from asymptomatic blood donors 1.3 and 
2.6 years before they developed symptoms of vCJD, the first time silent carriage has been identified. 
In a related study, PMCA correctly identified 14 vCJD cases among 153 controls, which included 
patients with sCJD and other neurological or neurodegenerative disorders[89].  
While there has been significant progress in vCJD test development, most notably the detection of 
PrP
TSE
 in pre-clinical samples[88], there remain substantial hurdles in respect of a high-throughput 
screening test. The PMCA assay has demonstrated the capacity to detect the minute amounts of 
PrP
TSE
 in sub-clinical samples but requires further validation on a larger sample set including non-
129MM PRNP genotype samples. Also, in its current format it is not practical as a high throughput 
screening test as it requires several days to complete, although its use as a vCJD diagnostic, or 
confirmatory method for screening test-reactive samples, looks promising. The DDA assay is more 
suited to development for high throughput screening than PMCA. However, to date its capacity to 
detect samples with vCJD is restricted to those with a clinical diagnosis and with a sensitivity of 70%, 
compared to 100% for PMCA. It remains to be seen if the test has the capacity to interdict samples 
taken from pre-clinical vCJD cases and the rarity of such samples complicates clarification of this 
issue. 
In the event that a suitably sensitive and specific high-throughput test is commercialised, it appears 
unlikely that implementation for universal donor testing can simply be assumed. The moral and 
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ethical issues associated with testing for an incurable disease are complex and given the low risk 
level outside countries directly impacted by vCJD, universal testing is unlikely to be cost-effective. 
Indeed, the potential refusal of donors to be tested leading to donor loss might precipitate supply 
shortages resulting in a net increased risk to recipients. The issues associated with counselling 
donors and recipients have been discussed in detail [91, 92]. The availability of a suitable 
confirmatory test is viewed as an essential pre-requisite to implementing universal screening. In the 
absence of a suitable confirmatory test, opt in/opt out testing (where donors could indicate their 
preference for notification in the event of a screening test reactive or confirmed positive result) is 
one suggested option.  
Unanswered questions and future directions 
Future management of the risk of transfusion-transmitted vCJD and CJD is unclear.  Current evidence 
suggests that the transmission of vCJD from the food-chain has been effectively eliminated, at least 
in the UK and, at least in the USA, regulators have established that donors are considered at risk only 
if their exposure in the UK was between 1980 and 1996.  It is to be presumed that such cut-off dates 
will also be implemented as other countries eliminate food-borne risk. Nevertheless, a taxing 
question is the extent to which those exposed before 1996 may be incubating infection; incubation 
periods beyond 40 years have been noted for kuru. One concern is that all but one of the clinically 
apparent vCJD cases have occurred among those with the 129MM PRNP genotype and this raises the 
question that the 129MV or 129VV genotypes may have a much longer incubation period.  As noted, 
the latest UK case of vCJD was in a 129MV individual [7], which may indicate the beginning of a 
second wave of the epidemic. 
In the UK, individuals born after 1996, and in theory not exposed to BSE in the food chain, might 
form a “lower risk” cohort for vCJD.  Their donations could then be preferentially used for recipients 
who also belong to the “lower risk” cohort having been born after the precautionary measures for 
food were enacted. It was suggested, for example, that FFP from this donor cohort could be ear-
marked “lower risk” and could replace the supplies of FFP being imported from outside the UK. The 
results of the Appendix III study have naturally led to more uncertainty about when exposure to BSE 
through diet in the UK can be said to have ceased also leading to a lack of confidence that a date can 
be defined for any cohort of “lower risk” donors. It also raises a question about the definition of a 
“lower risk” group of recipients and continued use of imported FFP for this group. 
The current outbreak of vCJD appears to be over for PRNP codon 129 methionineMM homozygotes, 
although there is some degree of concern about subsequent waves of disease among those already 
infected.  There is considerable uncertainty about the size of the infected population, and as long as 
the cohort that was exposed to BSE survives, there will be at least a perception of some (albeit 
small) risk to blood safety.  Accordingly, some precautionary measures will remain in place.  
Whether feasible testing methods for potential infectivity will be available or, if available, will be 
used, is an open question.  Certainly cost-benefit assessments have not favoured the adoption of 
prion filters, especially in view of existing evidence that their efficacy appears to be less than 
optimal.  It is possible that the apparent resolution of the BSE and vCJD epidemics will result in a 
reduction of public, political and financial interest in this field, which will be unfortunate, because 
there is much yet to be learned about TSE diseases and their management.  It is also reasonable to 
consider that there may be lessons for the future.  Is it possible that there could be further 
outbreaks of novel TSE diseases of zoonotic origin?  CWD of cervids is extraordinarily infectious in 
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nature and there have been some studies indicating the possibility of limited cross-species infection.  
As is true for other agents that may impact blood safety, continued alertness and surveillance is 
advisablenecessary. 
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Legend for Figure 1. 
 
Title - vCJD Cases Worldwide 
 
 Worldwide cumulative vCJD cases (n=230) by country and year compiled from; 
http://www.eurocjd.ed.ac.uk/surveillance data 1.html as of May 28, 2015 and 
http://www.cjd.ed.ac.uk/sites/default/files/figs050117.pdf as of April 24, 2017 
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